SHC2 and neoplasm: Apart from the PI3K/AKT pathway (CDC37, IL6R), Epidermal-Mesenchymal transition (IL6R, SHC2), tumour metastasis and T1/T2 activation are highlighted (DLL1, STAT4, IL6R).